We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: CagriSema
MedXY News
EnglishTag

CagriSema

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy
Clinical UpdatescagrilintideCagriSema

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy

By MedXY|Jun 9, 2026

REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management
CardiologyCagriSema
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
GLP-1 RA

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY|Feb 2, 2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduct

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity
Diabetes & EndocrinologycagrilintideCagriSema

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY|Oct 5, 2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities